RESUMEN
BACKGROUND: Cardiovascular diseases are the major cause of death globally and represent a major economic burden on health care systems. For patients with heart failure, atrial fibrillation or therapy-resistant hypertension, we have developed a novel integrated care concept (NICC) which combines telemedicine with intensive support by a care center, including a call center, an integrated care network including inpatient and outpatient care providers and guideline therapy for patients (Schmidt et al. 2018 Trials 19:120). Here, we describe challenges and solutions in patient recruitment and provide the statistical analysis plan. METHODS: The study CardioCare MV is a prospective, randomized, controlled, parallel-group, open-label, bi-center trial with two groups for comparing NICC with standard of care (SoC). Because of issues with patient enrollment we adapted the study plan after consultation with the Ethics Committee and the funding agency. We altered the analysis strategy for the primary endpoints, which led to a change in the required sample size. We also changed the access points to patients from inpatient hospitals specialized in the treatment of patients with cardiovascular disease to specialized practices. RESULTS: Recruitment of patients started on 1 December 2017, and first patient in was on 4 December 2017. Recruitment was completed on 15 August 2019 as planned according to the amended study plan. The follow-up period will end in August 2020. A total of 964 patients was enrolled into the trial. The statistical analysis plan was finalized prior to last patient in. Results will be available by the end of 2020. DISCUSSION: The trial will inform care providers whether quality of care can be improved by an integrated care concept providing telemedicine through a round-the-clock call center approach. We expect that cost of the NICC will be lower than standard care because of reduced hospitalizations. The trial will guide additional research to disentangle the effects of this complex intervention. TRIAL REGISTRATION: DRKS, ID: DRKS00013124. Registered on 5 October 2017 ClinicalTrials.gov, ID: NCT03317951. Registered on 17 October 2017.
Asunto(s)
Fibrilación Atrial/terapia , Prestación Integrada de Atención de Salud/métodos , Insuficiencia Cardíaca/terapia , Hipertensión/terapia , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Selección de Paciente , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Telemedicina/métodos , Enfermedad Crónica , Estudios de Seguimiento , Humanos , Tiempo de Internación , Estudios Prospectivos , Nivel de AtenciónRESUMEN
BACKGROUND: Low cancer clinical trial (CCT) enrollment may contribute to survival disparities affecting adolescents and young adults (AYAs) (ages 15-39 years). The objective of this study was to evaluate whether differences in CCT availability related to treatment site could explain the low CCT enrollment. METHODS: This prospective, observational cohort study was conducted at an academic children's hospital and its affiliated but geographically separated adult cancer hospital within a National Cancer Institute-designated Comprehensive Cancer Center. For consecutive, newly diagnosed AYA patients, it was determined whether an appropriate CCT existed nationally, was available at the treatment site, and was used for enrollment. Proportions of AYAs in these categories were compared between sites using the chi-square test. RESULTS: One hundred fifty-two consecutive AYA patients were included from the children's hospital (n = 68; ages 15-20 years) and the adult cancer hospital (n = 84; ages 18-39 years). Although there was no difference in CCT existence for individual AYA patients by site (children's hospital [36 of 68 patients; 52.9%] vs adult cancer hospital [45 of 84 patients; 53.6%]; P = .938), CCT availability was significantly lower at the adult cancer hospital (14 of 84 patients [16.7%] vs 30 of 68 [44.1%] at the children's hospital; P < .001). The proportion of AYAs enrolled was low at both sites (8 of 68 patients [11.8%] vs 6 of 84 patients [7.1%], respectively; P = .327). Fewer existing CCTs were available at the adult cancer hospital (4 of 27 patients [14.8%] vs 8 of 14 patients [57.1%], respectively), and those were directed toward solid tumors and new agents. CONCLUSIONS: Efforts to improve low CCT enrollment among AYAs should be differentiated by treatment site. In the adult setting, these efforts should be aimed at improving CCT availability by overcoming site-level barriers to opening existing CCTs.
Asunto(s)
Instituciones Oncológicas/estadística & datos numéricos , Ensayos Clínicos como Asunto/estadística & datos numéricos , Accesibilidad a los Servicios de Salud/estadística & datos numéricos , Hospitales Pediátricos/estadística & datos numéricos , Neoplasias/epidemiología , Neoplasias/terapia , Selección de Paciente , Adolescente , Adulto , Factores de Edad , Instituciones Oncológicas/organización & administración , Ensayos Clínicos como Asunto/organización & administración , Estudios de Cohortes , Femenino , Hospitales Pediátricos/organización & administración , Humanos , Masculino , Oncología Médica/organización & administración , Oncología Médica/normas , Oncología Médica/estadística & datos numéricos , Estudios Multicéntricos como Asunto/normas , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Estudios Prospectivos , Transición a la Atención de Adultos/organización & administración , Transición a la Atención de Adultos/normas , Transición a la Atención de Adultos/estadística & datos numéricos , Adulto JovenRESUMEN
At the design stage of a study, it is crucial to compute the sample size needed for treatment effect estimation with maximum precision and power. The optimal design depends on the costs, which may be known at the design stage, and on the outcome variances, which are unknown. A balanced design, optimal for homogeneous costs and variances, is typically used. An alternative to the balanced design is a design optimal for the known and possibly heterogeneous costs, and homogeneous variances, called costs considering design. Both designs suffer from loss of efficiency, compared with optimal designs for heterogeneous costs and variances. For 2 × 2 multicenter trials, we compute the relative efficiency of the balanced and the costs considering designs, relative to the optimal designs. We consider 2 heterogeneous costs and variance scenarios (in 1 scenario, 2 treatment conditions have small and 2 have large costs and variances; in the other scenario, 1 treatment condition has small, 2 have intermediate, and 1 has large costs and variances). Within these scenarios, we examine the relative efficiency of the balanced design and of the costs considering design as a function of the extents of heterogeneity of the costs and of the variances and of their congruence (congruent when the cheapest treatment has the smallest variance, incongruent when the cheapest treatment has the largest variance). We find that the costs considering design is generally more efficient than the balanced design, and we illustrate this theory on a 2 × 2 multicenter trial on lifestyle improvement of patients in general practices.
Asunto(s)
Ensayos Clínicos como Asunto/métodos , Bioestadística , Ensayos Clínicos como Asunto/economía , Ensayos Clínicos como Asunto/estadística & datos numéricos , Medicina General , Costos de la Atención en Salud , Promoción de la Salud , Humanos , Estilo de Vida , Modelos Lineales , Modelos Estadísticos , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Tamaño de la Muestra , Resultado del TratamientoRESUMEN
BACKGROUND: Oral iron-replacement therapy is the mainstay of treatment for iron-deficiency anemia, but it is often poorly tolerated or ineffective. Hemoglobin response at day 14 of oral iron may be useful in assessing whether and when to transition patients from oral to intravenous (IV) iron. METHODS: Pooled data from 5 randomized trials were analyzed to compare oral and IV iron-replacement therapy for iron-deficiency anemia. Treatment criteria and assignment to oral versus IV iron were defined per protocol; this analysis included only subjects receiving oral iron. Responders were subjects with ≥1.0-g/dL increases in hemoglobin at day 14, and nonresponders were those with smaller increases. Demographic and clinical characteristics were evaluated for association with hemoglobin response at multiple timepoints. RESULTS: Most subjects (72.8%) were classified as responders. The proportion of subjects with hemoglobin increases ≥1.0, ≥2.0, and ≥3.0 g/dL was greatest among those with postpartum anemia, intermediate among those with heavy uterine bleeding or gastrointestinal-related causes of anemia, and lowest among those with other causes; this proportion was also significantly greater among responders than nonresponders. A ≥1.0-g/dL increase in hemoglobin on day 14 most accurately predicted satisfactory overall hemoglobin response to oral iron on day 42/56 (sensitivity 90.1%; specificity 79.3%; positive and negative predictive values of 92.9% and 72.7%, respectively). Iron-replacement therapy improved quality of life and reduced fatigue. CONCLUSION: Hemoglobin responses <1.0 g/dL at day 14 of oral iron identify subjects with iron-deficiency anemia who should be transitioned to IV iron supplementation.
Asunto(s)
Administración Intravenosa , Administración Oral , Anemia Ferropénica/tratamiento farmacológico , Ferritinas/efectos de los fármacos , Compuestos Ferrosos/administración & dosificación , Hemoglobinas/efectos de los fármacos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Anemia Ferropénica/complicaciones , Suplementos Dietéticos , Fatiga/etiología , Femenino , Ferritinas/sangre , Compuestos Ferrosos/uso terapéutico , Hemoglobinas/análisis , Humanos , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Calidad de Vida , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Resultado del Tratamiento , Adulto JovenAsunto(s)
Fibrilación Atrial/complicaciones , Inhibidores del Factor Xa/uso terapéutico , Morfolinas/uso terapéutico , Estudios Multicéntricos como Asunto , Ensayos Clínicos Controlados Aleatorios como Asunto , Tiofenos/uso terapéutico , Trombofilia/tratamiento farmacológico , Adulto , Anciano , Anticoagulantes/efectos adversos , Anticoagulantes/uso terapéutico , Fibrilación Atrial/terapia , Cardioversión Eléctrica/métodos , Embolia/epidemiología , Embolia/etiología , Embolia/prevención & control , Inhibidores del Factor Xa/efectos adversos , Cardiopatías/mortalidad , Hemorragia/inducido químicamente , Humanos , Relación Normalizada Internacional , Persona de Mediana Edad , Morfolinas/efectos adversos , Estudios Multicéntricos como Asunto/métodos , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Infarto del Miocardio/epidemiología , Infarto del Miocardio/etiología , Infarto del Miocardio/prevención & control , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Proyectos de Investigación , Riesgo , Rivaroxabán , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/etiología , Accidente Cerebrovascular/prevención & control , Tiofenos/efectos adversos , Trombofilia/etiología , Factores de Tiempo , Resultado del Tratamiento , Vitamina K/antagonistas & inhibidores , Warfarina/efectos adversos , Warfarina/uso terapéuticoAsunto(s)
Quelantes/uso terapéutico , Terapia por Quelación , Enfermedad Coronaria/tratamiento farmacológico , Complicaciones de la Diabetes/tratamiento farmacológico , Ácido Edético/uso terapéutico , Metales Pesados , Infarto del Miocardio/prevención & control , Ensayos Clínicos como Asunto/estadística & datos numéricos , Enfermedad Coronaria/complicaciones , Complicaciones de la Diabetes/prevención & control , Ácido Edético/efectos adversos , Contaminantes Ambientales/efectos adversos , Humanos , Infusiones Intravenosas , Metales Pesados/efectos adversos , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Infarto del Miocardio/etiologíaRESUMEN
BACKGROUND: Cluster randomized trials are increasingly being used in healthcare evaluation to show the effectiveness of a specific intervention. Care pathways (CPs) are becoming a popular tool to improve the quality of health-care services provided to heart failure patients. In order to perform a well-designed cluster randomized trial to demonstrate the effectiveness of Usual care (UC) and CP in heart failure treatment, the intraclass correlation coefficient (ICC) should be available before conducting a trial to estimate the required sample size. This study reports ICCs for both demographical and outcome variables from cluster randomized trials of heart failure patients in UC and care pathways. METHODS: To calculate the degree of within-cluster dependence, the ICC and associated 95% confidence interval were calculated by a method based on analysis of variance. All analyses were performed in R software version 2.15.1. RESULTS: ICCs for baseline characteristics ranged from 0.025 to 0.058. The median value and interquartile range was 0.043 [0.026-0.052] for ICCs of baseline characteristics. Among baseline characteristics, the highest ICCs were found for admission by referral or admission from home (ICC = 0.058) and the disease severity at admission (ICC = 0.046). Corresponding ICCs for appropriateness of the stay, length of stay and hospitalization cost were 0.069, 0.063, and 0.001 in CP group and 0.203, 0.020, 0.046 for usual care, respectively. CONCLUSION: Reported values of ICCs from present care pathway trial and UC results for some common outcomes will be helpful for estimating sample size in future clustered randomized heart failure trials, in particular for the evaluation of care pathways.
Asunto(s)
Vías Clínicas , Insuficiencia Cardíaca/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto/métodos , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Intervalos de Confianza , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Tiempo de Internación/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/métodos , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Variaciones Dependientes del Observador , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Reproducibilidad de los Resultados , Tamaño de la Muestra , Estadística como Asunto , Resultado del TratamientoAsunto(s)
Estudios Observacionales como Asunto/estadística & datos numéricos , Modelos de Riesgos Proporcionales , Anciano , Causalidad , Quelantes/uso terapéutico , Terapia por Quelación , Estudios de Cohortes , Recolección de Datos , Femenino , Humanos , Hiperparatiroidismo Secundario/sangre , Hiperparatiroidismo Secundario/tratamiento farmacológico , Hiperparatiroidismo Secundario/etiología , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Estudios Observacionales como Asunto/métodos , Fósforo , Puntaje de Propensión , Diálisis Renal/efectos adversos , Proyectos de InvestigaciónRESUMEN
BACKGROUND: There is a growing interest in therapies that may augment motor recovery that could be initiated in the acute stroke unit and maintained through the rehabilitation period. Homogenization of the currently fragmented stroke clinicometrics is necessary before such multidisciplinary trials can be conducted. The supplementary motor scale of the NIH Stroke Scale (SMS-NIHSS) is a simple and reliable scale for assessing proximal and distal motor function in the upper and lower extremities. We hypothesized that the currently underutilized SMS-NIHSS is a valid tool for assessing motor recovery with prognosticative value. METHODS: We performed an analysis of SMS-NIHSS scores recorded in 1,281 patients enrolled in the Trial of ORG 10172 in Acute Stroke Treatment (TOAST). We plotted the probability of a favorable outcome (FO) and very favorable outcome (VFO) at 3 months based on the baseline SMS-NIHSS scores. In order to better study the relationship between SMS-NIHSS and 3-month functional outcome, we performed multivariate logistic regression analyses using both FO and VFO as outcome measures. Analyses were adjusted for potential confounders such as age, sex, side of the lesion, time from symptom onset to emergency room arrival, temperature, systolic blood pressure, blood glucose level and treatment group assignment (ORG 10172 vs. placebo). We also calculated the Spearman correlation coefficient between the SMS-NIHSS, Barthel Index (BI) and Glasgow Outcome Score (GOS) obtained at the 3-month visit. RESULTS: The mean SMS-NIHSS scores were 8.18 at baseline and 4.68 at 3 months. The SMS-NIHSS scores showed a gradual improvement during the first 3 months after stroke. There was a linear relationship between the baseline SMS-NIHSS scores and the probability of an FO or VFO at 3 months. The SMS-NIHSS baseline score was an independent predictor of FO (OR = 0.86; 95% CI 0.84-0.87; p < 0.0001) and VFO (OR = 0.85; 95% CI 0.84-0.87; p < 0.0001) at 3 months after adjusting for confounders. The degree of improvement in the SMS-NIHSS scores from baseline to 3 months was also independently associated with FO and VFO (p < 0.0001). At 3 months, SMS-NIHSS scores showed a strong correlation with the BI (r = -0.70; p < 0.0001) and GOS (r = 0.73; p < 0.0001). CONCLUSIONS: The SMS-NIHSS is a valid scale for assessing motor recovery with prognosticative value, and may be sensitive to changes during recovery. Given that the SMS-NIHSS is an extension of the widely accepted NIHSS, it could be easily implemented in trials conducted in a variety of clinical research settings, including acute stroke hospitals and rehabilitation units.
Asunto(s)
Actividad Motora , Trastornos del Movimiento/fisiopatología , Recuperación de la Función , Índice de Severidad de la Enfermedad , Rehabilitación de Accidente Cerebrovascular , Enfermedad Aguda , Anticoagulantes/uso terapéutico , Daño Encefálico Crónico/etiología , Daño Encefálico Crónico/fisiopatología , Isquemia Encefálica/tratamiento farmacológico , Isquemia Encefálica/rehabilitación , Sulfatos de Condroitina/uso terapéutico , Ensayos Clínicos como Asunto/estadística & datos numéricos , Factores de Confusión Epidemiológicos , Dermatán Sulfato/uso terapéutico , Femenino , Escala de Consecuencias de Glasgow , Heparitina Sulfato/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Trastornos del Movimiento/etiología , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Pronóstico , Estudios Retrospectivos , Accidente Cerebrovascular/complicaciones , Resultado del TratamientoRESUMEN
Adjuvant therapy represents the gold standard treatment for radically resected pancreatic cancer. Results from randomized clinical trials confirmed the efficacy of adjuvant therapy for pancreatic cancer but did not define what is the "right choice" in terms of type of antiblastic drug (among gemcitabine, 5-fluorouracil or other drugs), role of polychemotherapy and chemoradiotherapy. The objective of our study was to evaluate the efficacy and toxicity of adjuvant chemotherapy and chemoradiotherapy for radically resected pancreatic cancer through a systematic review of literature data, emphasizing the benefits regarding overall survival, disease-free survival and toxicity.
Asunto(s)
Pancreatectomía/métodos , Neoplasias Pancreáticas/cirugía , Antimetabolitos Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioradioterapia , Quimioterapia Adyuvante/efectos adversos , Quimioterapia Adyuvante/métodos , Ensayos Clínicos Fase II como Asunto/estadística & datos numéricos , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Terapia Combinada , Desoxicitidina/análogos & derivados , Desoxicitidina/uso terapéutico , Supervivencia sin Enfermedad , Doxorrubicina/administración & dosificación , Fluorouracilo/administración & dosificación , Fluorouracilo/uso terapéutico , Humanos , Mitomicina/administración & dosificación , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/radioterapia , Neoplasias Pancreáticas/terapia , Guías de Práctica Clínica como Asunto , Radioterapia Adyuvante/efectos adversos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Análisis de Supervivencia , GemcitabinaRESUMEN
The effect of deferasirox dosing tailored for iron burden and iron loading based on liver iron concentration (LIC) was assessed over 1 year in less versus more heavily iron-overloaded patients in a substudy of the Evaluation of Patients' Iron Chelation with Exjade®. Deferasirox starting dose was 10-30 mg/kg/day, depending on blood transfusion frequency, with recommended dose adjustments every 3 months. Therapeutic goals were LIC maintenance or reduction in patients with baseline LIC <7 or ≥7 mg Fe/g dry weight (dw), respectively. Changes in LIC (R2-magnetic resonance imaging) and serum ferritin after 1 year were assessed. Adverse events (AEs) and laboratory parameters were monitored throughout. Of 374 patients, 71 and 303 had baseline LIC <7 and ≥7 mg Fe/g dw, respectively; mean deferasirox doses were 20.7 and 27.1 mg/kg/day (overall average time to dose increase, 24 weeks). At 1 year, mean LIC and median serum ferritin levels were maintained in the low-iron cohort (-0.02 ± 2.4 mg Fe/g dw, -57 ng/mL; P = not significant) and significantly decreased in the high-iron cohort (-6.1 ± 9.1 mg Fe/g dw, -830 ng/mL; P < 0.0001). Drug-related gastrointestinal AEs, mostly mild to moderate, were more frequently reported in the <7 versus ≥7 mg Fe/g dw cohort (39.4 versus 20.8 %; P = 0.001) and were not confounded by diagnosis, dosing, ethnicity, or hepatitis B and/or C history. Reported serum creatinine increases did not increase in low- versus high-iron cohort patients. Deferasirox doses of 20 mg/kg/day maintained LIC <7 mg Fe/g dw and doses of 30 mg/kg/day were required for net iron reduction in the high-iron cohort, with clinically manageable safety profiles. The higher incidence of gastrointestinal AEs at lower iron burdens requires further investigation.
Asunto(s)
Benzoatos/uso terapéutico , Terapia por Quelación , Quelantes del Hierro/uso terapéutico , Sobrecarga de Hierro/tratamiento farmacológico , Hierro/análisis , Hígado/efectos de los fármacos , Imagen por Resonancia Magnética , Triazoles/uso terapéutico , Adolescente , Adulto , Benzoatos/administración & dosificación , Benzoatos/efectos adversos , Benzoatos/farmacología , Terapia por Quelación/efectos adversos , Niño , Preescolar , Colelitiasis/inducido químicamente , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Creatinina/sangre , Deferasirox , Edema/inducido químicamente , Etnicidad , Femenino , Ferritinas/sangre , Enfermedades Gastrointestinales/inducido químicamente , Enfermedades Hematológicas/complicaciones , Enfermedades Hematológicas/patología , Enfermedades Hematológicas/terapia , Hepatitis Viral Humana/complicaciones , Hepatitis Viral Humana/metabolismo , Hepatitis Viral Humana/patología , Humanos , Lactante , Quelantes del Hierro/administración & dosificación , Quelantes del Hierro/efectos adversos , Quelantes del Hierro/farmacología , Sobrecarga de Hierro/complicaciones , Sobrecarga de Hierro/metabolismo , Sobrecarga de Hierro/patología , Enfermedades Renales/sangre , Enfermedades Renales/inducido químicamente , Hígado/química , Masculino , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Estudios Prospectivos , Talasemia/complicaciones , Talasemia/metabolismo , Talasemia/patología , Talasemia/terapia , Reacción a la Transfusión , Triazoles/administración & dosificación , Triazoles/efectos adversos , Triazoles/farmacología , Adulto JovenRESUMEN
Despite improvement of prognosis, older age remains a negative prognostic factor in acute promyelocytic leukemia (APL). Reports on disease characteristics and outcome of older patients are conflicting. We therefore analyzed 91 newly diagnosed APL patients aged 60 years or older (30 % of 305 adults with APL) registered by the German AML Cooperative Group (AMLCG) since 1994; 68 patients (75 %) were treated in studies, 23 (25 %) were non-eligible, and 31 % had high-risk APL. Fifty-six patients received induction therapy with all-trans retinoic acid and TAD (6-thioguanine, cytarabine, daunorubicin), and consolidation and maintenance therapy. Treatment intensification with a second induction cycle (high dose cytarabine, mitoxantrone; HAM) was optional (n = 14). Twelve patients were randomized to another therapy not considered in this report. The early death rate was 48 % in non-eligible and 19 % in study patients. With the AMLCG regimen, 7-year overall, event-free and relapse-free survival (RFS) and cumulative incidence of relapse were 45 %, 40 %, 48 %, and 24 %, respectively. In patients treated with TAD-HAM induction, 7-year RFS was superior (83 %; p = 0.006) compared to TAD only, and no relapse was observed. In our registered elderly patients, we see a high rate of non-eligibility for treatment in studies and of high-risk APL. In patients who can undergo a curative approach, intensified chemotherapy is highly effective, but is restricted to a selection of patients. Therefore, new less toxic treatment approaches with broader applicability are needed. Elderly patients might be a particular target group for concepts with arsenic trioxide.
Asunto(s)
Leucemia Promielocítica Aguda/epidemiología , Factores de Edad , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Trióxido de Arsénico , Arsenicales/administración & dosificación , Médula Ósea/patología , Citarabina/administración & dosificación , Daunorrubicina/administración & dosificación , Supervivencia sin Enfermedad , Femenino , Estudios de Seguimiento , Alemania/epidemiología , Humanos , Estimación de Kaplan-Meier , Leucemia Promielocítica Aguda/sangre , Leucemia Promielocítica Aguda/tratamiento farmacológico , Leucemia Promielocítica Aguda/genética , Leucemia Promielocítica Aguda/mortalidad , Recuento de Leucocitos , Quimioterapia de Mantención , Masculino , Persona de Mediana Edad , Mitoxantrona/administración & dosificación , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Óxidos/administración & dosificación , Pronóstico , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Inducción de Remisión , Riesgo , Tioguanina/administración & dosificación , Resultado del Tratamiento , Tretinoina/administración & dosificaciónAsunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/uso terapéutico , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Morfolinas/uso terapéutico , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Tiofenos/uso terapéutico , Trombofilia/tratamiento farmacológico , beta-Alanina/análogos & derivados , Dabigatrán , Femenino , Humanos , Masculino , Rivaroxabán , beta-Alanina/uso terapéuticoAsunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/uso terapéutico , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Morfolinas/uso terapéutico , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Tiofenos/uso terapéutico , Trombofilia/tratamiento farmacológico , beta-Alanina/análogos & derivados , Dabigatrán , Femenino , Humanos , Masculino , Rivaroxabán , beta-Alanina/uso terapéuticoRESUMEN
New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa inhibitors (rivaroxaban and apixaban), and the third is a direct thrombin inhibitor (dabigatran). They have been separately compared to warfarin in large randomised trials. Our objective was to indirectly compare the three agents to each other for major efficacy and safety outcomes. Studies were assessed for comparability and the odds ratios of selected outcomes for each anticoagulant versus one another were estimated indirectly. The three cohorts differed significantly in terms of CHADS(2) score and the number of individuals with a past history of stroke, transient ischemic attack or systemic embolism. The estimated odds ratio of stroke or systemic embolism was 1.35 for rivaroxaban vs dabigatran 150 mg (p=0.04), 0.97 for rivaroxaban versus dabigatran 110 mg (p=0.81), 1.22 for apixaban versus dabigatran 150 mg (p=0.18), 0.88 for apixaban versus dabigatran 110 mg (p=0.34) and 0.90 for apixaban versus rivaroxaban (p=0.43). The estimated odds ratio of major bleeding was 1.10 for rivaroxaban versus dabigatran 150 mg (p=0.36), 1.28 for rivaroxaban versus dabigatran 110 mg (p=0.02), 0.74 for apixaban versus dabigatran 150 mg (p=0.004), 0.87 for apixaban versus dabigatran 110 mg (p=0.17) and 0.68 for apixaban versus rivaroxaban (p<0.001). In conclusion, the available data indicate no significant difference in efficacy between dabigatran 150 mg and apixaban for the prevention of stroke or systemic embolism in patients with non-valvular atrial fibrillation. It appears however that apixaban is associated with less major bleeding than dabigatran 150 mg or rivaroxaban and that rivaroxaban is less effective than dabigatran 150 mg in preventing stroke or systemic embolism. Such an indirect comparison should be used only to generate hypotheses which need to be tested in a dedicated randomised trial comparing the three drugs directly.
Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/uso terapéutico , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Morfolinas/uso terapéutico , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Pirazoles/uso terapéutico , Piridonas/uso terapéutico , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Tiofenos/uso terapéutico , Trombofilia/tratamiento farmacológico , beta-Alanina/análogos & derivados , Anciano , Anticoagulantes/efectos adversos , Antitrombinas/efectos adversos , Antitrombinas/uso terapéutico , Fibrilación Atrial/complicaciones , Bencimidazoles/efectos adversos , Dabigatrán , Embolia/epidemiología , Embolia/prevención & control , Inhibidores del Factor Xa , Femenino , Enfermedades de las Válvulas Cardíacas/complicaciones , Hemorragia/inducido químicamente , Hemorragia/epidemiología , Humanos , Ataque Isquémico Transitorio/epidemiología , Ataque Isquémico Transitorio/prevención & control , Masculino , Morfolinas/efectos adversos , Pirazoles/efectos adversos , Piridonas/efectos adversos , Rivaroxabán , Prevención Secundaria , Índice de Severidad de la Enfermedad , Accidente Cerebrovascular/epidemiología , Accidente Cerebrovascular/prevención & control , Tiofenos/efectos adversos , Trombofilia/etiología , Vitamina K/antagonistas & inhibidores , Warfarina/efectos adversos , Warfarina/uso terapéutico , beta-Alanina/efectos adversos , beta-Alanina/uso terapéuticoRESUMEN
OBJECTIVES: Specific immunotherapy with the grass allergy immunotherapy tablet (AIT) has been developed as an effective, well tolerated, and convenient treatment for grass pollen induced seasonal allergic rhinoconjunctivitis (ARC). Six phase II/III randomized, placebo-controlled trials with the duration of a single grass pollen season of treatment using the SQ-standardized grass AIT, Grazax (Phleum pratense, 75,000 SQ-T/2,800 BAU, ALK, Denmark), have been published previously. This review compares results from these trials. METHODS: As outcome measures and methods of assessing them were similar across the trials, we have summarized the main efficacy findings (Total Combined Score [TCS], average daily rhinoconjunctivitis symptom and medication scores, percentage of well days, quality of life scores) during a single season of treatment with grass AIT in adults and children with seasonal ARC. RESULTS: The results of the European and North American trials were similar. Compared with the placebo group, who received symptomatic medications only, treatment with grass AIT resulted in fewer rhinoconjunctivitis symptoms, a lower intake of symptomatic medication, better patient self-rated quality of life and a greater percentage of well days during the entire grass pollen season. The data indicate that grass AIT treatment is equally effective in adults and children; the measured effect varies with pollen exposure, but is comparable across regions and continents, with a consistent difference compared with placebo in TCS that was above 20% for all trials. Local adverse events were experienced by the majority of patients. These reactions were generally mild to moderate in severity and transient in duration. Systemic adverse events were rare. CONCLUSIONS: This review confirms SQ-standardized grass AIT as a suitable therapeutic option for seasonal use in patients aged 5 years or older with grass pollen induced ARC.
Asunto(s)
Conjuntivitis Alérgica/terapia , Desensibilización Inmunológica/métodos , Extractos Vegetales/administración & dosificación , Poaceae/inmunología , Rinitis Alérgica Estacional/terapia , Alérgenos/administración & dosificación , Alérgenos/inmunología , Ensayos Clínicos Fase II como Asunto/estadística & datos numéricos , Ensayos Clínicos Fase III como Asunto/estadística & datos numéricos , Conjuntivitis Alérgica/complicaciones , Esquema de Medicación , Humanos , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Extractos Vegetales/inmunología , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Estándares de Referencia , Rinitis Alérgica Estacional/complicaciones , Comprimidos/administración & dosificación , Comprimidos/normasRESUMEN
BACKGROUND: Secretory phospholipase A2 (sPLA(2)) and lipoprotein-associated phospholipase A2 (Lp-PLA(2)) are enzyme biomarkers of increased cardiovascular risk and targets of emerging therapeutic agents. Their relationship to cardiovascular events in the setting of high-dose statin therapy compared with placebo in patients with acute coronary syndrome is not known. METHODS AND RESULTS: sPLA(2) and Lp-PLA(2) mass and activity were measured in 2587 patients in the Myocardial Ischemia Reduction With Acute Cholesterol Lowering (MIRACL) trial at baseline and after 16 weeks of treatment with atorvastatin 80 mg/d or placebo. Baseline levels of sPLA(2) and Lp-PLA(2) mass and activity were not associated with the primary efficacy measure of the trial of death, myocardial infarction, or unstable angina. However, in the overall cohort, baseline sPLA(2) mass predicted risk of death after multivariable adjustment (hazard ratio for 2-fold increase, 1.30; 95% confidence interval, 1.09-1.56; P=0.004). This association remained significant when examined separately in the placebo group but not in the atorvastatin group. Compared with placebo, atorvastatin reduced median sPLA(2) mass (-32.1% versus -23.1%), sPLA(2) activity (-29.5% versus -19.2%), Lp-PLA(2) mass (-35.8% versus -6.2%), and Lp-PLA(2) activity (-24.3% versus 5.4%; P<0.001 for all). Atorvastatin reduced the hazard of death associated with elevated sPLA(2) mass and activity by ≈50%. CONCLUSIONS: sPLA(2) mass independently predicts death during a 16-week period after acute coronary syndrome. High-dose atorvastatin significantly reduces sPLA(2) and Lp-PLA(2) mass and activity after acute coronary syndrome and mitigates the risk of death associated with sPLA(2) mass. Atorvastatin may exert antiinflammatory effects on phospholipases that contribute to its therapeutic benefit after acute coronary syndrome.
Asunto(s)
1-Alquil-2-acetilglicerofosfocolina Esterasa/sangre , Síndrome Coronario Agudo/epidemiología , Ácidos Heptanoicos/uso terapéutico , Isquemia Miocárdica/epidemiología , Fosfolipasas A2 Secretoras/sangre , Pirroles/uso terapéutico , Síndrome Coronario Agudo/sangre , Síndrome Coronario Agudo/complicaciones , Síndrome Coronario Agudo/enzimología , Anciano , Aterosclerosis/sangre , Aterosclerosis/enzimología , Aterosclerosis/etiología , Atorvastatina , Biomarcadores , Proteína C-Reactiva/análisis , Método Doble Ciego , Femenino , Estudios de Seguimiento , Ácidos Heptanoicos/administración & dosificación , Humanos , Hipercolesterolemia/sangre , Hipercolesterolemia/complicaciones , Hipercolesterolemia/tratamiento farmacológico , Hipercolesterolemia/enzimología , Inflamación/sangre , Inflamación/enzimología , Lipoproteínas/sangre , Masculino , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Isquemia Miocárdica/sangre , Isquemia Miocárdica/complicaciones , Isquemia Miocárdica/enzimología , Oxidación-Reducción , Pirroles/administración & dosificación , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Estudios Retrospectivos , Riesgo , Factores de Riesgo , Análisis de SupervivenciaRESUMEN
The propensity score method is widely used in clinical studies to estimate the effect of a treatment with two levels on patient's outcomes. However, due to the complexity of many diseases, an effective treatment often involves multiple components. For example, in the practice of Traditional Chinese Medicine (TCM), an effective treatment may include multiple components, e.g. Chinese herbs, acupuncture, and massage therapy. In clinical trials involving TCM, patients could be randomly assigned to either the treatment or control group, but they or their doctors may make different choices about which treatment component to use. As a result, treatment components are not randomly assigned. Rosenbaum and Rubin proposed the propensity score method for binary treatments, and Imbens extended their work to multiple treatments. These authors defined the generalized propensity score as the conditional probability of receiving a particular level of the treatment given the pre-treatment variables. In the present work, we adopted this approach and developed a statistical methodology based on the generalized propensity score in order to estimate treatment effects in the case of multiple treatments. Two methods were discussed and compared: propensity score regression adjustment and propensity score weighting. We used these methods to assess the relative effectiveness of individual treatments in the multiple-treatment IMPACT clinical trial. The results reveal that both methods perform well when the sample size is moderate or large.
Asunto(s)
Medicina Tradicional China , Modelos Biológicos , Modelos Estadísticos , Puntaje de Propensión , Resultado del Tratamiento , Anciano , Antidepresivos/uso terapéutico , Simulación por Computador/estadística & datos numéricos , Depresión/terapia , Femenino , Humanos , Masculino , Servicios de Salud Mental/estadística & datos numéricos , Persona de Mediana Edad , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricosRESUMEN
Protracted preoperative radiochemotherapy with a 5-FU-based scheme, or a short course of preoperative radiotherapy without chemotherapy, are the standard neoadjuvant treatments for resectable stage II-III rectal cancer. Local failure rates are low and reproducible, between 6 and 15% when followed with a "Total Mesorectal Excision". Nevertheless, the therapeutic strategy needs to be improved: distant metastatic recurrence rates remain stable around 30 to 35%, while both sphincter and sexual sequels are still significant. The aim of the present paper was to analyse the ongoing trials listed on the following search engines: the Institut National du Cancer in France, the National Cancer Institute and the National Institute of Health in the United States, and the major cooperative groups. Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery". Twenty-three trials were selected and classified in different groups, each of them addressing a question of strategy: (1) place of adjuvant chemotherapy; (2) optimization of preoperative radiotherapy; (3) evaluation of new radiosensitization protocols and/or neoadjuvant chemotherapy; (4) optimization of techniques and timing of surgery; (5) place of radiotherapy for non resectable or metastatic tumors.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante , Terapia Neoadyuvante , Neoplasias del Recto/tratamiento farmacológico , Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Anticuerpos Monoclonales/administración & dosificación , Anticuerpos Monoclonales Humanizados , Antimetabolitos Antineoplásicos/administración & dosificación , Antimetabolitos Antineoplásicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Camptotecina/administración & dosificación , Camptotecina/análogos & derivados , Capecitabina , Cetuximab , Ensayos Clínicos Fase II como Asunto/estadística & datos numéricos , Ensayos Clínicos Fase III como Asunto , Terapia Combinada , Desoxicitidina/administración & dosificación , Desoxicitidina/análogos & derivados , Fluorouracilo/administración & dosificación , Fluorouracilo/análogos & derivados , Predicción , Humanos , Irinotecán , Leucovorina/administración & dosificación , Estudios Multicéntricos como Asunto/estadística & datos numéricos , Compuestos Organoplatinos/administración & dosificación , Oxaliplatino , Fármacos Sensibilizantes a Radiaciones/administración & dosificación , Radioterapia Conformacional/efectos adversos , Radioterapia Conformacional/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto/estadística & datos numéricos , Neoplasias del Recto/radioterapia , Neoplasias del Recto/cirugía , Factores de Tiempo , Resultado del TratamientoRESUMEN
Lennox-Gastaut syndrome (LGS) is an intractable childhood-onset epileptic encephalopathy. Seizure freedom is rare in LGS. One of the hallmarks of LGS is medical intractability, with generally poor response to antiepileptic drugs (AEDs). Nevertheless, several treatment options are available that can mitigate the severity of seizures and curtail their frequency. New AEDs have been validated in randomized, controlled trials for the treatment of seizures in LGS. In some cases, nonpharmacologic options may be effective, although more data are needed to confirm efficacy outcomes. Comprehensive patient assessments are critical to achieve an optimal AED treatment regimen and minimize the potential for adverse effects.